Markets
Apple shares cut to “hold” from “buy” by analyst citing valuation
(Kevin Carter/Getty Images)

Analyst: Apple is too expensive; buy Amazon or Alphabet instead

Needham analysts cut Apple’s buy rating Wednesday, citing valuation and competitive threats.

Matt Phillips

Analysts at Needham axed their rating on Apple Wednesday, lowering the iPhone maker to “hold” from “buy,” in light of growing competitive threats from AI and sluggish iPhone sales (which got what may have been merely a tariff-fueled bump last quarter), both of which are tough to square with a premium valuation. They wrote:

“AAPL’s integrated hardware and software ecosystem has best-in-class moats, we believe. However, AAPL is not immune to technological disruption, which is what GenAI represents, in our view. Because AAPL has a 15%-30% take rate of revs earned on its hardware, every Big Tech company is building platforms designed to displace AAPL's integrated hardware and software products in a GenAI world.”

Among other issues, they spotlight Apple’s capex expenditures — skimpy by the standards of so-called hyperscalers like Microsoft and Meta — as an indication that the company is complacent about the long-term AI threat.

They also zero in on a global smartphone market slowdown as being a more proximate problem for sales and profits over the next year, as well as potential hits from regulatory shifts such as recent antitrust decisions in the US that could impact their services revenue.

All of these issues make it hard to justify the multiple of 26x earnings over the next 12 months that the market is putting on the shares, Needham analysts said.

Google parent Alphabet, for example, has a multiple of just 17x, while Meta, which is expected to grow at a much faster rate (14% vs. Apple’s 5%), trades at roughly the same valuation as Apple.

“We caution that AAPL has material risks to its revenue growth, margins, and valuation multiple,” they wrote, adding, “We prefer Alphabet and Amazon to Apple.”

More Markets

See all Markets
(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most-searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be short hand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January more people in the US are searching for Eli Lilly’s weight loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides," a catch-all term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lilly's diabetes and weight loss drugs have outsold Novo's and that gap is expected to widen this year.

markets

Crypto crumble smokes bitcoin-sensitive stocks and speculative tech

It’s a rough day out there, with the pain in the crypto markets being felt among select subgroups of US equities. Shortly before 2 p.m. ET on Wednesday here’s a snapshot of where some of the worst pinches are.

There is some overlap between some of these baskets, for instance bitcoin treasury company Strategy figures both in the “bitcoin sensitive” and “meme” basket. But in general it’s just a pretty ugly day for some of the more speculative corners of the stock market.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.